These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21520077)

  • 21. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
    Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
    Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
    Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
    Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
    Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
    Hari M; Yang H; Zeng C; Canizales M; Cabral F
    Cell Motil Cytoskeleton; 2003 Sep; 56(1):45-56. PubMed ID: 12905530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.
    Kamath K; Wilson L; Cabral F; Jordan MA
    J Biol Chem; 2005 Apr; 280(13):12902-7. PubMed ID: 15695826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
    Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
    Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tubulins as therapeutic targets in cancer: from bench to bedside.
    Katsetos CD; Dráber P
    Curr Pharm Des; 2012; 18(19):2778-92. PubMed ID: 22390762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
    Wehbe H; Kearney CM; Pinney KG
    Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.